POPULARITY
10 episodes with milind
6 episodes with milind
7 episodes with milind
7 episodes with milind
10 episodes with milind
6 episodes with milind
6 episodes with milind
4 episodes with milind
4 episodes with milind
In this episode, I sit down with Milind Soman and Ankita Konwar after completing our annual ritual of the ‘Last Long Run', this time from Porbandar to Dwarkadhish. We dive into their personal journeys, motivations, and life philosophies. Ankita shares her inspiring story of overcoming her fear of swimming to becoming an open water swimmer, as well as her experience of quitting alcohol and embracing a life of balance and discipline. Milind reflects on the importance of shutting out external noise to connect with your true self. He talks about his motivations, the return of Pinkathon and its plans for expansion, why he encourages pushups for selfies, and how fitness can transform lives. We also discuss how this memorable run shaped our thoughts, their guiding principles in life, and how both Milind and Ankita continue to inspire a nation to live healthier, more mindful lives. Tune in for a conversation filled with wisdom and inspiration! We hope you will enjoy this episode and let us know your thoughts in the comments. If you have any guest suggestions for our podcast, mail us at:- findyourultra@gmail.com Follow Find Your Ultra's Social Media Handles: YouTube: / @findyourultra Instagram: / find_your_ultra Facebook: / findyourultra WhatsApp: https://whatsapp.com/channel/0029Vakf... For any other queries EMAIL: findyourultra@gmail.com Follow Ankita Konwar's Social Media Handles:- Instagram: / ankita_earthy Facebook: / ankitamkonwar X: https://x.com/5earthy Follow Milind Soman's Social Media Handles:- Instagram: / milindrunning Facebook: / milindrunning X: https://x.com/milindrunning
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
The Best New Year Inspiration In this inspiring 10-minute episode of Find Your Ultra, we sit down with Usha Soman, the 85-year-old mother of Milind Soman, who continues to prove that age is no barrier to living an active and adventurous life. Starting her fitness journey in her 60s, Usha has gone on to conquer some of the world's most iconic treks, including the Everest Base Camp, Annapurna, and Mount Kilimanjaro. She's not slowing down anytime soon! Usha shares her passion for long walks, her approach to challenging herself, and her secret to staying fit and motivated as she grows older. Whether you're looking for a dose of inspiration to kickstart your New Year or proof that it's never too late to begin, this episode will leave you uplifted and energized. Don't miss this special conversation with a true role model who embodies strength, resilience, and the spirit of continuous growth. We hope you will enjoy this episode and let us know your thoughts in the comments. _____ If you have any guest suggestions for our podcast, mail us at:- findyourultra@gmail.com Follow Find Your Ultra's Social Media Handles: YouTube: https://www.youtube.com/@FindYourUltra Instagram: https://www.instagram.com/find_your_ultra/ Facebook: https://www.facebook.com/findyourultra/ WhatsApp: https://whatsapp.com/channel/0029Vakfwa0DjiOca1x9vI1G For any other queries EMAIL: findyourultra@gmail.com Follow Usha Soman's Social Media Handles:- Instagram: https://www.instagram.com/somanusha/
What happens when procurement evolves from being transaction-focused to becoming a true business partner? Find out in this episode.Host Richard McIntosh speaks with Milind Tailor, Global Head, Resale Products & Services Procurement at Diebold Nixdorf, about the transformative journey of procurement business partnering. Milind shares how procurement can go beyond cost-cutting to build trust, foster supplier innovation, and align with business goals to drive revenue and operational excellence.You'll learn:1. How Procurement Business Partnering serves as an operating model to align procurement with strategic business goals2. How to use the Supplier Performance Index as a governance tool to evaluate and enhance supplier relationships3. Why the Trust Equation is vital for building strong stakeholder and supplier alliances4. The role of a balanced scorecard in measuring procurement's impact beyond cost5. Essential advice for starting and excelling in a procurement career___________Get in touch with Milind Tailor on LinkedIn: https://www.linkedin.com/in/milind-deepak-tailor/___________Details about Diebold Nixdorf:Website: https://DieboldNixdorf.comIndustry: IT Services and IT ConsultingCompany size: 10,001+ employeesHeadquarters: North Canton, OhioFounded: 1859___________About the host Richard McIntosh:Richard McIntosh, Partner at H&Z Management Consulting, has spent over 23 years helping procurement leaders succeed. Richard is an avid rugby fan, and a children's rugby coach, with a passion for helping children to become their best selves through sports. He spends his time outside of work with his wife and children. Get in touch with Richard McIntosh on LinkedIn: https://www.linkedin.com/in/mcintosh-richard/ ___________The Procurement Initiative Leaders Podcast is powered by H&Z Management Consulting in collaboration with SAWOO.
FinovateFall Best of Show winner Illuma on call-center security and AI-based fraud
They said Maharashtra cricketers cannot succeed while putting in the hard yards on Mumbai maidans. He did. They said Maharashtra batters couldn't score away from Nehru Stadium. He did. They said Maharashtra as a team can rarely deliver consistently. He was instrumental in shaping the golden generation of Maharashtra's Ranji Trophy team that fared consistently for a decade starting the mid-80s. Milind Gunjal proved virtually everyone wrong with his stellar batting at all the levels he got an opportunity at. Still, the only thing he couldn't change was to earn the India cap and end up as one of the top names on the long list of "Maharashtra's unfortunate cricketers to have not represented India" in international cricket. Let's walk down the memory lane with Milind Gunjal himself. मुंबईच्या मैदानावर महाराष्ट्राचे क्रिकेटपटू यशस्वी होऊ शकत नाहीत, असं म्हणायचे. ते झाले. असंही म्हणायचे - खरं तर हिणवायचे - कि नेहरू स्टेडियमपासून दूर महाराष्ट्राचे फलंदाज धावा करू शकत नाहीत. त्यांनी कुटल्या. अशीही वदंता असायची कि एक संघ म्हणून महाराष्ट्र क्वचितच सातत्यपूर्ण कामगिरी करायचा. त्यांनी महाराष्ट्र रणजी संघाची 'गोल्डन जनरेशन' घडवण्यात मोलाची भूमिका बजावली. मिलिंद गुंजाळ यांनी सर्व स्तरांवर आपल्या उत्कृष्ट फलंदाजीने अक्षरशः प्रत्येकाला चुकीचे सिद्ध केले. तरीही, ते फक्त एक गोष्ट बदलू शकले नाहीत, ती म्हणजे भारताची कॅप मिळवणे. त्यामुळेच गुंजाळांचे नाव "महाराष्ट्राचे दुर्दैवी क्रिकेटपटू ज्यांनी भारताचे प्रतिनिधित्व केले नाही" या लांबलचक यादीतील शीर्ष नावांपैकी एक आहे. जाऊया आठवणींच्या गावी खुद्द मिलिंद गुंजाळ यांच्यासोबत.
In this episode of Amplify Insider, Milind Pathak, Executive Vice-President, Product & Marketing at Route Mobile, joins CNBC-TV18's Mridu Bhandari to discuss how businesses can enhance their digital experience through robust security measures. Learn about the key trends, challenges, and solutions in the digital landscape that are shaping the future of secure communications. Tune in to gain insights on how to stay ahead in today's rapidly evolving digital ecosystem.
"He eats Mumbai cricket, he sleeps Mumbai cricket and he breathes Mumbai cricket." The description fits Milind Rege, a stalwart! A prolific allrounder and a multiple Ranji Trophy champion. Rege recovered from a heart ailment to return to lead Mumbai. After retiring early in quest of a prospering corporate career, Rege thrived as a selector. He spotted a talent as progious as his childhood friend Sunil Gavaskar in Sachin Tendulkar and convinced his selection committee seniors to pick Tendulkar in the Ranji Trophy squad. Then on, till picking the likes of Prithvi Shaw and Yashasvi Jaiswal, Rege has played a a crucial role in Mumbai cricket's success story. In a freewheeling chat on Kattyawarchya Gappa with Amol Karhadkar, The Hindu's sports journalist, Rege narrates his terrific tale मुंबई क्रिकेवर बोलणारे अनेक जण भेटतील. पण १९६५ पासून तब्बल सहा दशकं मुंबई क्रिकेटमध्ये सक्रिय सहभागी असलेले मिलिंद रेगे म्हणजे मुंबई क्रिकेटचा एनसायक्लोपिडिआच आहेत. सुनील गावस्कर ते पृथ्वी शॉ- यशस्वी जयस्वाल या सर्व पिढ्यांमध्ये समान धागा असेल, तर ते मिलिंग रेगे. गावस्कर आणि रेगेंची बालपणापासून असलेली दोस्ती सर्वश्रुत आहे, परंतु रेगेंचे मुंबईसाठी खेळताना आलेले अनुभव, तारुण्यात आलेल्या हार्ट-अटॅकनंतर त्यांनी केलेला कमबॅक, या गोष्टीही तेवढ्याच रंजक आहेत. प्रथम-श्रेणी क्रिकेटमधून ऐन बहरात असताना निवृत्ती घेतल्यानंतर मुंबई क्रिकेटमधील विविध जबाबदाऱ्या - विशेषतः निवड समिती प्रमुख हि भूमिका - त्यांनी समर्थपणे सांभाळल्या आहेत. रेगे सरांशी 'द हिंदू' चे क्रीडा पत्रकार अमोल क-हाडकर यांनी मारलेल्या 'कट्ट्यावरच्या गप्पा'ETA: asap
Who knew?Join Innovation Blab/Failure - the Podcast in a double-header. A two-fer. “Episode 80 - Broken Down Cars” and “Episode 81 - The Singularity is Nigh.” Our special guests are … well … special.Sydney Robinson is CEO and co-founder of Vessl Prosthetics, an Ontario-based startup that is hellbent on improving the lives of below-knee amputees and on proving that not all orthopedic startups end up like broken down cars along the road to success. We think they've got a shot at both. If Sydney can survive 45 minutes of our drivel, she should have no problem navigating the tough medical industry market.Milind Sawant is an AI guru, currently with Siemens Healthcare and leading a team of 50 engineers and a $15M budget to drive AI integration into medical systems. It's no surprise that Milind is a big fan of AI and the promise it brings to healthcare. That shone through despite Jeff's probing questions, Dave's skepticism and Mark's snoring. (OK, we exaggerate: Mark was no noisier catching Zs than a former president at a felony trial).Who knew that podcasts could be so much better than a presidential debate between octogenarians?
Who knew?Join Innovation Blab/Failure - the Podcast in a double-header. A two-fer. “Episode 80 - Broken Down Cars” and “Episode 81 - The Singularity is Nigh.” Our special guests are … well … special.Sydney Robinson is CEO and co-founder of Vessl Prosthetics, an Ontario-based startup that is hellbent on improving the lives of below-knee amputees and on proving that not all orthopedic startups end up like broken down cars along the road to success. We think they've got a shot at both. If Sydney can survive 45 minutes of our drivel, she should have no problem navigating the tough medical industry market.Milind Sawant is an AI guru, currently with Siemens Healthcare and leading a team of 50 engineers and a $15M budget to drive AI integration into medical systems. It's no surprise that Milind is a big fan of AI and the promise it brings to healthcare. That shone through despite Jeff's probing questions, Dave's skepticism and Mark's snoring. (OK, we exaggerate: Mark was no noisier catching Zs than a former president at a felony trial).Who knew that podcasts could be so much better than a presidential debate between octogenarians?
Join us for an engaging podcast with Milind Shintre as we explore Marathi names, their meanings, and tips on naming a child. Milind also shares some humorous Marathi names, offering a delightful mix of culture and laughter.
Today's guest is Dr. Milind Sawant, Founder and Lead of the AI/ML & DFSS Centre of Excellence at Siemens Healthineers. Dr. Sawant joins us in today's program to talk about the top impediments to developing and deploying AI in any organization and avoiding the typical mistakes that life sciences and healthcare firms tend to make in the process. Later in the program, Dr. Sawant talks about the enormous changes that AI capabilities are bringing to diagnostics workflows and what the future of these industries will look like as these changes become more commonplace. This episode is sponsored by iMerit. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
►Think School's flagship Communication course with live doubt sessions : https://thethinkschool.com/sp/communication-masterclass/ ►Follow Think School Social Media: Youtube: https://www.youtube.com/@ThinkSchool Instagram: https://www.instagram.com/thethinkschool?igsh=NWg2ZXRyZmdsM2ds&utm_source=qr This is a conversation with Milind Murli Deora an Indian politician and former Union Minister of State for Communications & Information Technology and Shipping, Here he opens up about Modi's Vision for India, How Congress Blunders affected India's growth?, What is CAA and NRC?, and How e-governance can benefit India ? and the growth of Mumbai.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DMR865. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
Our next 2 big events are AI UX and the World's Fair. Join and apply to speak/sponsor!Due to timing issues we didn't have an interview episode to share with you this week, but not to worry, we have more than enough “weekend special” content in the backlog for you to get your Latent Space fix, whether you like thinking about the big picture, or learning more about the pod behind the scenes, or talking Groq and GPUs, or AI Leadership, or Personal AI. Enjoy!AI BreakdownThe indefatigable NLW had us back on his show for an update on the Four Wars, covering Sora, Suno, and the reshaped GPT-4 Class Landscape:and a longer segment on AI Engineering trends covering the future LLM landscape (Llama 3, GPT-5, Gemini 2, Claude 4), Open Source Models (Mistral, Grok), Apple and Meta's AI strategy, new chips (Groq, MatX) and the general movement from baby AGIs to vertical Agents:Thursday Nights in AIWe're also including swyx's interview with Josh Albrecht and Ali Rohde to reintroduce swyx and Latent Space to a general audience, and engage in some spicy Q&A:Dylan Patel on GroqWe hosted a private event with Dylan Patel of SemiAnalysis (our last pod here):Not all of it could be released so we just talked about our Groq estimates:Milind Naphade - Capital OneIn relation to conversations at NeurIPS and Nvidia GTC and upcoming at World's Fair, we also enjoyed chatting with Milind Naphade about his AI Leadership work at IBM, Cisco, Nvidia, and now leading the AI Foundations org at Capital One. We covered:* Milind's learnings from ~25 years in machine learning * His first paper citation was 24 years ago* Lessons from working with Jensen Huang for 6 years and being CTO of Metropolis * Thoughts on relevant AI research* GTC takeaways and what makes NVIDIA specialIf you'd like to work on building solutions rather than platform (as Milind put it), his Applied AI Research team at Capital One is hiring, which falls under the Capital One Tech team.Personal AI MeetupIt all started with a meme:Within days of each other, BEE, FRIEND, EmilyAI, Compass, Nox and LangFriend were all launching personal AI wearables and assistants. So we decided to put together a the world's first Personal AI meetup featuring creators and enthusiasts of wearables. The full video is live now, with full show notes within.Timestamps* [00:01:13] AI Breakdown Part 1* [00:02:20] Four Wars* [00:13:45] Sora* [00:15:12] Suno* [00:16:34] The GPT-4 Class Landscape* [00:17:03] Data War: Reddit x Google* [00:21:53] Gemini 1.5 vs Claude 3* [00:26:58] AI Breakdown Part 2* [00:27:33] Next Frontiers: Llama 3, GPT-5, Gemini 2, Claude 4* [00:31:11] Open Source Models - Mistral, Grok* [00:34:13] Apple MM1* [00:37:33] Meta's $800b AI rebrand* [00:39:20] AI Engineer landscape - from baby AGIs to vertical Agents* [00:47:28] Adept episode - Screen Multimodality* [00:48:54] Top Model Research from January Recap* [00:53:08] AI Wearables* [00:57:26] Groq vs Nvidia month - GPU Chip War* [01:00:31] Disagreements* [01:02:08] Summer 2024 Predictions* [01:04:18] Thursday Nights in AI - swyx* [01:33:34] Dylan Patel - Semianalysis + Latent Space Live Show* [01:34:58] GroqTranscript[00:00:00] swyx: Welcome to the Latent Space Podcast Weekend Edition. This is Charlie, your AI co host. Swyx and Alessio are off for the week, making more great content. We have exciting interviews coming up with Elicit, Chroma, Instructor, and our upcoming series on NSFW, Not Safe for Work AI. In today's episode, we're collating some of Swyx and Alessio's recent appearances, all in one place for you to find.[00:00:32] swyx: In part one, we have our first crossover pod of the year. In our listener survey, several folks asked for more thoughts from our two hosts. In 2023, Swyx and Alessio did crossover interviews with other great podcasts like the AI Breakdown, Practical AI, Cognitive Revolution, Thursday Eye, and Chinatalk, all of which you can find in the Latentspace About page.[00:00:56] swyx: NLW of the AI Breakdown asked us back to do a special on the 4Wars framework and the AI engineer scene. We love AI Breakdown as one of the best examples Daily podcasts to keep up on AI news, so we were especially excited to be back on Watch out and take[00:01:12] NLW: care[00:01:13] AI Breakdown Part 1[00:01:13] NLW: today on the AI breakdown. Part one of my conversation with Alessio and Swix from Latent Space.[00:01:19] NLW: All right, fellas, welcome back to the AI Breakdown. How are you doing? I'm good. Very good. With the last, the last time we did this show, we were like, oh yeah, let's do check ins like monthly about all the things that are going on and then. Of course, six months later, and, you know, the, the, the world has changed in a thousand ways.[00:01:36] NLW: It's just, it's too busy to even, to even think about podcasting sometimes. But I, I'm super excited to, to be chatting with you again. I think there's, there's a lot to, to catch up on, just to tap in, I think in the, you know, in the beginning of 2024. And, and so, you know, we're gonna talk today about just kind of a, a, a broad sense of where things are in some of the key battles in the AI space.[00:01:55] NLW: And then the, you know, one of the big things that I, that I'm really excited to have you guys on here for us to talk about where, sort of what patterns you're seeing and what people are actually trying to build, you know, where, where developers are spending their, their time and energy and, and, and any sort of, you know, trend trends there, but maybe let's start I guess by checking in on a framework that you guys actually introduced, which I've loved and I've cribbed a couple of times now, which is this sort of four wars of the, of the AI stack.[00:02:20] Four Wars[00:02:20] NLW: Because first, since I have you here, I'd love, I'd love to hear sort of like where that started gelling. And then and then maybe we can get into, I think a couple of them that are you know, particularly interesting, you know, in the, in light of[00:02:30] swyx: some recent news. Yeah, so maybe I'll take this one. So the four wars is a framework that I came up around trying to recap all of 2023.[00:02:38] swyx: I tried to write sort of monthly recap pieces. And I was trying to figure out like what makes one piece of news last longer than another or more significant than another. And I think it's basically always around battlegrounds. Wars are fought around limited resources. And I think probably the, you know, the most limited resource is talent, but the talent expresses itself in a number of areas.[00:03:01] swyx: And so I kind of focus on those, those areas at first. So the four wars that we cover are the data wars, the GPU rich, poor war, the multi modal war, And the RAG and Ops War. And I think you actually did a dedicated episode to that, so thanks for covering that. Yeah, yeah.[00:03:18] NLW: Not only did I do a dedicated episode, I actually used that.[00:03:22] NLW: I can't remember if I told you guys. I did give you big shoutouts. But I used it as a framework for a presentation at Intel's big AI event that they hold each year, where they have all their folks who are working on AI internally. And it totally resonated. That's amazing. Yeah, so, so, what got me thinking about it again is specifically this inflection news that we recently had, this sort of, you know, basically, I can't imagine that anyone who's listening wouldn't have thought about it, but, you know, inflection is a one of the big contenders, right?[00:03:53] NLW: I think probably most folks would have put them, you know, just a half step behind the anthropics and open AIs of the world in terms of labs, but it's a company that raised 1. 3 billion last year, less than a year ago. Reed Hoffman's a co founder Mustafa Suleyman, who's a co founder of DeepMind, you know, so it's like, this is not a a small startup, let's say, at least in terms of perception.[00:04:13] NLW: And then we get the news that basically most of the team, it appears, is heading over to Microsoft and they're bringing in a new CEO. And you know, I'm interested in, in, in kind of your take on how much that reflects, like hold aside, I guess, you know, all the other things that it might be about, how much it reflects this sort of the, the stark.[00:04:32] NLW: Brutal reality of competing in the frontier model space right now. And, you know, just the access to compute.[00:04:38] Alessio: There are a lot of things to say. So first of all, there's always somebody who's more GPU rich than you. So inflection is GPU rich by startup standard. I think about 22, 000 H100s, but obviously that pales compared to the, to Microsoft.[00:04:55] Alessio: The other thing is that this is probably good news, maybe for the startups. It's like being GPU rich, it's not enough. You know, like I think they were building something pretty interesting in, in pi of their own model of their own kind of experience. But at the end of the day, you're the interface that people consume as end users.[00:05:13] Alessio: It's really similar to a lot of the others. So and we'll tell, talk about GPT four and cloud tree and all this stuff. GPU poor, doing something. That the GPU rich are not interested in, you know we just had our AI center of excellence at Decibel and one of the AI leads at one of the big companies was like, Oh, we just saved 10 million and we use these models to do a translation, you know, and that's it.[00:05:39] Alessio: It's not, it's not a GI, it's just translation. So I think like the inflection part is maybe. A calling and a waking to a lot of startups then say, Hey, you know, trying to get as much capital as possible, try and get as many GPUs as possible. Good. But at the end of the day, it doesn't build a business, you know, and maybe what inflection I don't, I don't, again, I don't know the reasons behind the inflection choice, but if you say, I don't want to build my own company that has 1.[00:06:05] Alessio: 3 billion and I want to go do it at Microsoft, it's probably not a resources problem. It's more of strategic decisions that you're making as a company. So yeah, that was kind of my. I take on it.[00:06:15] swyx: Yeah, and I guess on my end, two things actually happened yesterday. It was a little bit quieter news, but Stability AI had some pretty major departures as well.[00:06:25] swyx: And you may not be considering it, but Stability is actually also a GPU rich company in the sense that they were the first new startup in this AI wave to brag about how many GPUs that they have. And you should join them. And you know, Imadis is definitely a GPU trader in some sense from his hedge fund days.[00:06:43] swyx: So Robin Rhombach and like the most of the Stable Diffusion 3 people left Stability yesterday as well. So yesterday was kind of like a big news day for the GPU rich companies, both Inflection and Stability having sort of wind taken out of their sails. I think, yes, it's a data point in the favor of Like, just because you have the GPUs doesn't mean you can, you automatically win.[00:07:03] swyx: And I think, you know, kind of I'll echo what Alessio says there. But in general also, like, I wonder if this is like the start of a major consolidation wave, just in terms of, you know, I think that there was a lot of funding last year and, you know, the business models have not been, you know, All of these things worked out very well.[00:07:19] swyx: Even inflection couldn't do it. And so I think maybe that's the start of a small consolidation wave. I don't think that's like a sign of AI winter. I keep looking for AI winter coming. I think this is kind of like a brief cold front. Yeah,[00:07:34] NLW: it's super interesting. So I think a bunch of A bunch of stuff here.[00:07:38] NLW: One is, I think, to both of your points, there, in some ways, there, there had already been this very clear demarcation between these two sides where, like, the GPU pores, to use the terminology, like, just weren't trying to compete on the same level, right? You know, the vast majority of people who have started something over the last year, year and a half, call it, were racing in a different direction.[00:07:59] NLW: They're trying to find some edge somewhere else. They're trying to build something different. If they're, if they're really trying to innovate, it's in different areas. And so it's really just this very small handful of companies that are in this like very, you know, it's like the coheres and jaspers of the world that like this sort of, you know, that are that are just sort of a little bit less resourced than, you know, than the other set that I think that this potentially even applies to, you know, everyone else that could clearly demarcate it into these two, two sides.[00:08:26] NLW: And there's only a small handful kind of sitting uncomfortably in the middle, perhaps. Let's, let's come back to the idea of, of the sort of AI winter or, you know, a cold front or anything like that. So this is something that I, I spent a lot of time kind of thinking about and noticing. And my perception is that The vast majority of the folks who are trying to call for sort of, you know, a trough of disillusionment or, you know, a shifting of the phase to that are people who either, A, just don't like AI for some other reason there's plenty of that, you know, people who are saying, You Look, they're doing way worse than they ever thought.[00:09:03] NLW: You know, there's a lot of sort of confirmation bias kind of thing going on. Or two, media that just needs a different narrative, right? Because they're sort of sick of, you know, telling the same story. Same thing happened last summer, when every every outlet jumped on the chat GPT at its first down month story to try to really like kind of hammer this idea that that the hype was too much.[00:09:24] NLW: Meanwhile, you have, you know, just ridiculous levels of investment from enterprises, you know, coming in. You have, you know, huge, huge volumes of, you know, individual behavior change happening. But I do think that there's nothing incoherent sort of to your point, Swyx, about that and the consolidation period.[00:09:42] NLW: Like, you know, if you look right now, for example, there are, I don't know, probably 25 or 30 credible, like, build your own chatbot. platforms that, you know, a lot of which have, you know, raised funding. There's no universe in which all of those are successful across, you know, even with a, even, even with a total addressable market of every enterprise in the world, you know, you're just inevitably going to see some amount of consolidation.[00:10:08] NLW: Same with, you know, image generators. There are, if you look at A16Z's top 50 consumer AI apps, just based on, you know, web traffic or whatever, they're still like I don't know, a half. Dozen or 10 or something, like, some ridiculous number of like, basically things like Midjourney or Dolly three. And it just seems impossible that we're gonna have that many, you know, ultimately as, as, as sort of, you know, going, going concerned.[00:10:33] NLW: So, I don't know. I, I, I think that the, there will be inevitable consolidation 'cause you know. It's, it's also what kind of like venture rounds are supposed to do. You're not, not everyone who gets a seed round is supposed to get to series A and not everyone who gets a series A is supposed to get to series B.[00:10:46] NLW: That's sort of the natural process. I think it will be tempting for a lot of people to try to infer from that something about AI not being as sort of big or as as sort of relevant as, as it was hyped up to be. But I, I kind of think that's the wrong conclusion to come to.[00:11:02] Alessio: I I would say the experimentation.[00:11:04] Alessio: Surface is a little smaller for image generation. So if you go back maybe six, nine months, most people will tell you, why would you build a coding assistant when like Copilot and GitHub are just going to win everything because they have the data and they have all the stuff. If you fast forward today, A lot of people use Cursor everybody was excited about the Devin release on Twitter.[00:11:26] Alessio: There are a lot of different ways of attacking the market that are not completion of code in the IDE. And even Cursors, like they evolved beyond single line to like chat, to do multi line edits and, and all that stuff. Image generation, I would say, yeah, as a, just as from what I've seen, like maybe the product innovation has slowed down at the UX level and people are improving the models.[00:11:50] Alessio: So the race is like, how do I make better images? It's not like, how do I make the user interact with the generation process better? And that gets tough, you know? It's hard to like really differentiate yourselves. So yeah, that's kind of how I look at it. And when we think about multimodality, maybe the reason why people got so excited about Sora is like, oh, this is like a completely It's not a better image model.[00:12:13] Alessio: This is like a completely different thing, you know? And I think the creative mind It's always looking for something that impacts the viewer in a different way, you know, like they really want something different versus the developer mind. It's like, Oh, I, I just, I have this like very annoying thing I want better.[00:12:32] Alessio: I have this like very specific use cases that I want to go after. So it's just different. And that's why you see a lot more companies in image generation. But I agree with you that. If you fast forward there, there's not going to be 10 of them, you know, it's probably going to be one or[00:12:46] swyx: two. Yeah, I mean, to me, that's why I call it a war.[00:12:49] swyx: Like, individually, all these companies can make a story that kind of makes sense, but collectively, they cannot all be true. Therefore, they all, there is some kind of fight over limited resources here. Yeah, so[00:12:59] NLW: it's interesting. We wandered very naturally into sort of another one of these wars, which is the multimodality kind of idea, which is, you know, basically a question of whether it's going to be these sort of big everything models that end up winning or whether, you know, you're going to have really specific things, you know, like something, you know, Dolly 3 inside of sort of OpenAI's larger models versus, you know, a mid journey or something like that.[00:13:24] NLW: And at first, you know, I was kind of thinking like, For most of the last, call it six months or whatever, it feels pretty definitively both and in some ways, you know, and that you're, you're seeing just like great innovation on sort of the everything models, but you're also seeing lots and lots happen at sort of the level of kind of individual use cases.[00:13:45] Sora[00:13:45] NLW: But then Sora comes along and just like obliterates what I think anyone thought you know, where we were when it comes to video generation. So how are you guys thinking about this particular battle or war at the moment?[00:13:59] swyx: Yeah, this was definitely a both and story, and Sora tipped things one way for me, in terms of scale being all you need.[00:14:08] swyx: And the benefit, I think, of having multiple models being developed under one roof. I think a lot of people aren't aware that Sora was developed in a similar fashion to Dolly 3. And Dolly3 had a very interesting paper out where they talked about how they sort of bootstrapped their synthetic data based on GPT 4 vision and GPT 4.[00:14:31] swyx: And, and it was just all, like, really interesting, like, if you work on one modality, it enables you to work on other modalities, and all that is more, is, is more interesting. I think it's beneficial if it's all in the same house, whereas the individual startups who don't, who sort of carve out a single modality and work on that, definitely won't have the state of the art stuff on helping them out on synthetic data.[00:14:52] swyx: So I do think like, The balance is tilted a little bit towards the God model companies, which is challenging for the, for the, for the the sort of dedicated modality companies. But everyone's carving out different niches. You know, like we just interviewed Suno ai, the sort of music model company, and, you know, I don't see opening AI pursuing music anytime soon.[00:15:12] Suno[00:15:12] swyx: Yeah,[00:15:13] NLW: Suno's been phenomenal to play with. Suno has done that rare thing where, which I think a number of different AI product categories have done, where people who don't consider themselves particularly interested in doing the thing that the AI enables find themselves doing a lot more of that thing, right?[00:15:29] NLW: Like, it'd be one thing if Just musicians were excited about Suno and using it but what you're seeing is tons of people who just like music all of a sudden like playing around with it and finding themselves kind of down that rabbit hole, which I think is kind of like the highest compliment that you can give one of these startups at the[00:15:45] swyx: early days of it.[00:15:46] swyx: Yeah, I, you know, I, I asked them directly, you know, in the interview about whether they consider themselves mid journey for music. And he had a more sort of nuanced response there, but I think that probably the business model is going to be very similar because he's focused on the B2C element of that. So yeah, I mean, you know, just to, just to tie back to the question about, you know, You know, large multi modality companies versus small dedicated modality companies.[00:16:10] swyx: Yeah, highly recommend people to read the Sora blog posts and then read through to the Dali blog posts because they, they strongly correlated themselves with the same synthetic data bootstrapping methods as Dali. And I think once you make those connections, you're like, oh, like it, it, it is beneficial to have multiple state of the art models in house that all help each other.[00:16:28] swyx: And these, this, that's the one thing that a dedicated modality company cannot do.[00:16:34] The GPT-4 Class Landscape[00:16:34] NLW: So I, I wanna jump, I wanna kind of build off that and, and move into the sort of like updated GPT-4 class landscape. 'cause that's obviously been another big change over the last couple months. But for the sake of completeness, is there anything that's worth touching on with with sort of the quality?[00:16:46] NLW: Quality data or sort of a rag ops wars just in terms of, you know, anything that's changed, I guess, for you fundamentally in the last couple of months about where those things stand.[00:16:55] swyx: So I think we're going to talk about rag for the Gemini and Clouds discussion later. And so maybe briefly discuss the data piece.[00:17:03] Data War: Reddit x Google[00:17:03] swyx: I think maybe the only new thing was this Reddit deal with Google for like a 60 million dollar deal just ahead of their IPO, very conveniently turning Reddit into a AI data company. Also, very, very interestingly, a non exclusive deal, meaning that Reddit can resell that data to someone else. And it probably does become table stakes.[00:17:23] swyx: A lot of people don't know, but a lot of the web text dataset that originally started for GPT 1, 2, and 3 was actually scraped from GitHub. from Reddit at least the sort of vote scores. And I think, I think that's a, that's a very valuable piece of information. So like, yeah, I think people are figuring out how to pay for data.[00:17:40] swyx: People are suing each other over data. This, this, this war is, you know, definitely very, very much heating up. And I don't think, I don't see it getting any less intense. I, you know, next to GPUs, data is going to be the most expensive thing in, in a model stack company. And. You know, a lot of people are resorting to synthetic versions of it, which may or may not be kosher based on how far along or how commercially blessed the, the forms of creating that synthetic data are.[00:18:11] swyx: I don't know if Alessio, you have any other interactions with like Data source companies, but that's my two cents.[00:18:17] Alessio: Yeah yeah, I actually saw Quentin Anthony from Luther. ai at GTC this week. He's also been working on this. I saw Technium. He's also been working on the data side. I think especially in open source, people are like, okay, if everybody is putting the gates up, so to speak, to the data we need to make it easier for people that don't have 50 million a year to get access to good data sets.[00:18:38] Alessio: And Jensen, at his keynote, he did talk about synthetic data a little bit. So I think that's something that we'll definitely hear more and more of in the enterprise, which never bodes well, because then all the, all the people with the data are like, Oh, the enterprises want to pay now? Let me, let me put a pay here stripe link so that they can give me 50 million.[00:18:57] Alessio: But it worked for Reddit. I think the stock is up. 40 percent today after opening. So yeah, I don't know if it's all about the Google deal, but it's obviously Reddit has been one of those companies where, hey, you got all this like great community, but like, how are you going to make money? And like, they try to sell the avatars.[00:19:15] Alessio: I don't know if that it's a great business for them. The, the data part sounds as an investor, you know, the data part sounds a lot more interesting than, than consumer[00:19:25] swyx: cosmetics. Yeah, so I think, you know there's more questions around data you know, I think a lot of people are talking about the interview that Mira Murady did with the Wall Street Journal, where she, like, just basically had no, had no good answer for where they got the data for Sora.[00:19:39] swyx: I, I think this is where, you know, there's, it's in nobody's interest to be transparent about data, and it's, it's kind of sad for the state of ML and the state of AI research but it is what it is. We, we have to figure this out as a society, just like we did for music and music sharing. You know, in, in sort of the Napster to Spotify transition, and that might take us a decade.[00:19:59] swyx: Yeah, I[00:20:00] NLW: do. I, I agree. I think, I think that you're right to identify it, not just as that sort of technical problem, but as one where society has to have a debate with itself. Because I think that there's, if you rationally within it, there's Great kind of points on all side, not to be the sort of, you know, person who sits in the middle constantly, but it's why I think a lot of these legal decisions are going to be really important because, you know, the job of judges is to listen to all this stuff and try to come to things and then have other judges disagree.[00:20:24] NLW: And, you know, and have the rest of us all debate at the same time. By the way, as a total aside, I feel like the synthetic data right now is like eggs in the 80s and 90s. Like, whether they're good for you or bad for you, like, you know, we, we get one study that's like synthetic data, you know, there's model collapse.[00:20:42] NLW: And then we have like a hint that llama, you know, to the most high performance version of it, which was one they didn't release was trained on synthetic data. So maybe it's good. It's like, I just feel like every, every other week I'm seeing something sort of different about whether it's a good or bad for, for these models.[00:20:56] swyx: Yeah. The branding of this is pretty poor. I would kind of tell people to think about it like cholesterol. There's good cholesterol, bad cholesterol. And you can have, you know, good amounts of both. But at this point, it is absolutely without a doubt that most large models from here on out will all be trained as some kind of synthetic data and that is not a bad thing.[00:21:16] swyx: There are ways in which you can do it poorly. Whether it's commercial, you know, in terms of commercial sourcing or in terms of the model performance. But it's without a doubt that good synthetic data is going to help your model. And this is just a question of like where to obtain it and what kinds of synthetic data are valuable.[00:21:36] swyx: You know, if even like alpha geometry, you know, was, was a really good example from like earlier this year.[00:21:42] NLW: If you're using the cholesterol analogy, then my, then my egg thing can't be that far off. Let's talk about the sort of the state of the art and the, and the GPT 4 class landscape and how that's changed.[00:21:53] Gemini 1.5 vs Claude 3[00:21:53] NLW: Cause obviously, you know, sort of the, the two big things or a couple of the big things that have happened. Since we last talked, we're one, you know, Gemini first announcing that a model was coming and then finally it arriving, and then very soon after a sort of a different model arriving from Gemini and and Cloud three.[00:22:11] NLW: So I guess, you know, I'm not sure exactly where the right place to start with this conversation is, but, you know, maybe very broadly speaking which of these do you think have made a bigger impact? Thank you.[00:22:20] Alessio: Probably the one you can use, right? So, Cloud. Well, I'm sure Gemini is going to be great once they let me in, but so far I haven't been able to.[00:22:29] Alessio: I use, so I have this small podcaster thing that I built for our podcast, which does chapters creation, like named entity recognition, summarization, and all of that. Cloud Tree is, Better than GPT 4. Cloud2 was unusable. So I use GPT 4 for everything. And then when Opus came out, I tried them again side by side and I posted it on, on Twitter as well.[00:22:53] Alessio: Cloud is better. It's very good, you know, it's much better, it seems to me, it's much better than GPT 4 at doing writing that is more, you know, I don't know, it just got good vibes, you know, like the GPT 4 text, you can tell it's like GPT 4, you know, it's like, it always uses certain types of words and phrases and, you know, maybe it's just me because I've now done it for, you know, So, I've read like 75, 80 generations of these things next to each other.[00:23:21] Alessio: Clutter is really good. I know everybody is freaking out on twitter about it, my only experience of this is much better has been on the podcast use case. But I know that, you know, Quran from from News Research is a very big opus pro, pro opus person. So, I think that's also It's great to have people that actually care about other models.[00:23:40] Alessio: You know, I think so far to a lot of people, maybe Entropic has been the sibling in the corner, you know, it's like Cloud releases a new model and then OpenAI releases Sora and like, you know, there are like all these different things, but yeah, the new models are good. It's interesting.[00:23:55] NLW: My my perception is definitely that just, just observationally, Cloud 3 is certainly the first thing that I've seen where lots of people.[00:24:06] NLW: They're, no one's debating evals or anything like that. They're talking about the specific use cases that they have, that they used to use chat GPT for every day, you know, day in, day out, that they've now just switched over. And that has, I think, shifted a lot of the sort of like vibe and sentiment in the space too.[00:24:26] NLW: And I don't necessarily think that it's sort of a A like full you know, sort of full knock. Let's put it this way. I think it's less bad for open AI than it is good for anthropic. I think that because GPT 5 isn't there, people are not quite willing to sort of like, you know get overly critical of, of open AI, except in so far as they're wondering where GPT 5 is.[00:24:46] NLW: But I do think that it makes, Anthropic look way more credible as a, as a, as a player, as a, you know, as a credible sort of player, you know, as opposed to to, to where they were.[00:24:57] Alessio: Yeah. And I would say the benchmarks veil is probably getting lifted this year. I think last year. People were like, okay, this is better than this on this benchmark, blah, blah, blah, because maybe they did not have a lot of use cases that they did frequently.[00:25:11] Alessio: So it's hard to like compare yourself. So you, you defer to the benchmarks. I think now as we go into 2024, a lot of people have started to use these models from, you know, from very sophisticated things that they run in production to some utility that they have on their own. Now they can just run them side by side.[00:25:29] Alessio: And it's like, Hey, I don't care that like. The MMLU score of Opus is like slightly lower than GPT 4. It just works for me, you know, and I think that's the same way that traditional software has been used by people, right? Like you just strive for yourself and like, which one does it work, works best for you?[00:25:48] Alessio: Like nobody looks at benchmarks outside of like sales white papers, you know? And I think it's great that we're going more in that direction. We have a episode with Adapt coming out this weekend. I'll and some of their model releases, they specifically say, We do not care about benchmarks, so we didn't put them in, you know, because we, we don't want to look good on them.[00:26:06] Alessio: We just want the product to work. And I think more and more people will, will[00:26:09] swyx: go that way. Yeah. I I would say like, it does take the wind out of the sails for GPT 5, which I know where, you know, Curious about later on. I think anytime you put out a new state of the art model, you have to break through in some way.[00:26:21] swyx: And what Claude and Gemini have done is effectively take away any advantage to saying that you have a million token context window. Now everyone's just going to be like, Oh, okay. Now you just match the other two guys. And so that puts An insane amount of pressure on what gpt5 is going to be because it's just going to have like the only option it has now because all the other models are multimodal all the other models are long context all the other models have perfect recall gpt5 has to match everything and do more to to not be a flop[00:26:58] AI Breakdown Part 2[00:26:58] NLW: hello friends back again with part two if you haven't heard part one of this conversation i suggest you go check it out but to be honest they are kind of actually separable In this conversation, we get into a topic that I think Alessio and Swyx are very well positioned to discuss, which is what developers care about right now, what people are trying to build around.[00:27:16] NLW: I honestly think that one of the best ways to see the future in an industry like AI is to try to dig deep on what developers and entrepreneurs are attracted to build, even if it hasn't made it to the news pages yet. So consider this your preview of six months from now, and let's dive in. Let's bring it to the GPT 5 conversation.[00:27:33] Next Frontiers: Llama 3, GPT-5, Gemini 2, Claude 4[00:27:33] NLW: I mean, so, so I think that that's a great sort of assessment of just how the stakes have been raised, you know is your, I mean, so I guess maybe, maybe I'll, I'll frame this less as a question, just sort of something that, that I, that I've been watching right now, the only thing that makes sense to me with how.[00:27:50] NLW: Fundamentally unbothered and unstressed OpenAI seems about everything is that they're sitting on something that does meet all that criteria, right? Because, I mean, even in the Lex Friedman interview that, that Altman recently did, you know, he's talking about other things coming out first. He's talking about, he's just like, he, listen, he, he's good and he could play nonchalant, you know, if he wanted to.[00:28:13] NLW: So I don't want to read too much into it, but. You know, they've had so long to work on this, like unless that we are like really meaningfully running up against some constraint, it just feels like, you know, there's going to be some massive increase, but I don't know. What do you guys think?[00:28:28] swyx: Hard to speculate.[00:28:29] swyx: You know, at this point, they're, they're pretty good at PR and they're not going to tell you anything that they don't want to. And he can tell you one thing and change their minds the next day. So it's, it's, it's really, you know, I've always said that model version numbers are just marketing exercises, like they have something and it's always improving and at some point you just cut it and decide to call it GPT 5.[00:28:50] swyx: And it's more just about defining an arbitrary level at which they're ready and it's up to them on what ready means. We definitely did see some leaks on GPT 4. 5, as I think a lot of people reported and I'm not sure if you covered it. So it seems like there might be an intermediate release. But I did feel, coming out of the Lex Friedman interview, that GPT 5 was nowhere near.[00:29:11] swyx: And you know, it was kind of a sharp contrast to Sam talking at Davos in February, saying that, you know, it was his top priority. So I find it hard to square. And honestly, like, there's also no point Reading too much tea leaves into what any one person says about something that hasn't happened yet or has a decision that hasn't been taken yet.[00:29:31] swyx: Yeah, that's, that's my 2 cents about it. Like, calm down, let's just build .[00:29:35] Alessio: Yeah. The, the February rumor was that they were gonna work on AI agents, so I don't know, maybe they're like, yeah,[00:29:41] swyx: they had two agent two, I think two agent projects, right? One desktop agent and one sort of more general yeah, sort of GPTs like agent and then Andre left, so he was supposed to be the guy on that.[00:29:52] swyx: What did Andre see? What did he see? I don't know. What did he see?[00:29:56] Alessio: I don't know. But again, it's just like the rumors are always floating around, you know but I think like, this is, you know, we're not going to get to the end of the year without Jupyter you know, that's definitely happening. I think the biggest question is like, are Anthropic and Google.[00:30:13] Alessio: Increasing the pace, you know, like it's the, it's the cloud four coming out like in 12 months, like nine months. What's the, what's the deal? Same with Gemini. They went from like one to 1. 5 in like five days or something. So when's Gemini 2 coming out, you know, is that going to be soon? I don't know.[00:30:31] Alessio: There, there are a lot of, speculations, but the good thing is that now you can see a world in which OpenAI doesn't rule everything. You know, so that, that's the best, that's the best news that everybody got, I would say.[00:30:43] swyx: Yeah, and Mistral Large also dropped in the last month. And, you know, not as, not quite GPT 4 class, but very good from a new startup.[00:30:52] swyx: So yeah, we, we have now slowly changed in landscape, you know. In my January recap, I was complaining that nothing's changed in the landscape for a long time. But now we do exist in a world, sort of a multipolar world where Cloud and Gemini are legitimate challengers to GPT 4 and hopefully more will emerge as well hopefully from meta.[00:31:11] Open Source Models - Mistral, Grok[00:31:11] NLW: So speak, let's actually talk about sort of the open source side of this for a minute. So Mistral Large, notable because it's, it's not available open source in the same way that other things are, although I think my perception is that the community has largely given them Like the community largely recognizes that they want them to keep building open source stuff and they have to find some way to fund themselves that they're going to do that.[00:31:27] NLW: And so they kind of understand that there's like, they got to figure out how to eat, but we've got, so, you know, there there's Mistral, there's, I guess, Grok now, which is, you know, Grok one is from, from October is, is open[00:31:38] swyx: sourced at, yeah. Yeah, sorry, I thought you thought you meant Grok the chip company.[00:31:41] swyx: No, no, no, yeah, you mean Twitter Grok.[00:31:43] NLW: Although Grok the chip company, I think is even more interesting in some ways, but and then there's the, you know, obviously Llama3 is the one that sort of everyone's wondering about too. And, you know, my, my sense of that, the little bit that, you know, Zuckerberg was talking about Llama 3 earlier this year, suggested that, at least from an ambition standpoint, he was not thinking about how do I make sure that, you know, meta content, you know, keeps, keeps the open source thrown, you know, vis a vis Mistral.[00:32:09] NLW: He was thinking about how you go after, you know, how, how he, you know, releases a thing that's, you know, every bit as good as whatever OpenAI is on at that point.[00:32:16] Alessio: Yeah. From what I heard in the hallways at, at GDC, Llama 3, the, the biggest model will be, you 260 to 300 billion parameters, so that that's quite large.[00:32:26] Alessio: That's not an open source model. You know, you cannot give people a 300 billion parameters model and ask them to run it. You know, it's very compute intensive. So I think it is, it[00:32:35] swyx: can be open source. It's just, it's going to be difficult to run, but that's a separate question.[00:32:39] Alessio: It's more like, as you think about what they're doing it for, you know, it's not like empowering the person running.[00:32:45] Alessio: llama. On, on their laptop, it's like, oh, you can actually now use this to go after open AI, to go after Anthropic, to go after some of these companies at like the middle complexity level, so to speak. Yeah. So obviously, you know, we estimate Gentala on the podcast, they're doing a lot here, they're making PyTorch better.[00:33:03] Alessio: You know, they want to, that's kind of like maybe a little bit of a shorted. Adam Bedia, in a way, trying to get some of the CUDA dominance out of it. Yeah, no, it's great. The, I love the duck destroying a lot of monopolies arc. You know, it's, it's been very entertaining. Let's bridge[00:33:18] NLW: into the sort of big tech side of this, because this is obviously like, so I think actually when I did my episode, this was one of the I added this as one of as an additional war that, that's something that I'm paying attention to.[00:33:29] NLW: So we've got Microsoft's moves with inflection, which I think pretend, potentially are being read as A shift vis a vis the relationship with OpenAI, which also the sort of Mistral large relationship seems to reinforce as well. We have Apple potentially entering the race, finally, you know, giving up Project Titan and and, and kind of trying to spend more effort on this.[00:33:50] NLW: Although, Counterpoint, we also have them talking about it, or there being reports of a deal with Google, which, you know, is interesting to sort of see what their strategy there is. And then, you know, Meta's been largely quiet. We kind of just talked about the main piece, but, you know, there's, and then there's spoilers like Elon.[00:34:07] NLW: I mean, you know, what, what of those things has sort of been most interesting to you guys as you think about what's going to shake out for the rest of this[00:34:13] Apple MM1[00:34:13] swyx: year? I'll take a crack. So the reason we don't have a fifth war for the Big Tech Wars is that's one of those things where I just feel like we don't cover differently from other media channels, I guess.[00:34:26] swyx: Sure, yeah. In our anti interestness, we actually say, like, we try not to cover the Big Tech Game of Thrones, or it's proxied through Twitter. You know, all the other four wars anyway, so there's just a lot of overlap. Yeah, I think absolutely, personally, the most interesting one is Apple entering the race.[00:34:41] swyx: They actually released, they announced their first large language model that they trained themselves. It's like a 30 billion multimodal model. People weren't that impressed, but it was like the first time that Apple has kind of showcased that, yeah, we're training large models in house as well. Of course, like, they might be doing this deal with Google.[00:34:57] swyx: I don't know. It sounds very sort of rumor y to me. And it's probably, if it's on device, it's going to be a smaller model. So something like a Jemma. It's going to be smarter autocomplete. I don't know what to say. I'm still here dealing with, like, Siri, which hasn't, probably hasn't been updated since God knows when it was introduced.[00:35:16] swyx: It's horrible. I, you know, it, it, it makes me so angry. So I, I, one, as an Apple customer and user, I, I'm just hoping for better AI on Apple itself. But two, they are the gold standard when it comes to local devices, personal compute and, and trust, like you, you trust them with your data. And. I think that's what a lot of people are looking for in AI, that they have, they love the benefits of AI, they don't love the downsides, which is that you have to send all your data to some cloud somewhere.[00:35:45] swyx: And some of this data that we're going to feed AI is just the most personal data there is. So Apple being like one of the most trusted personal data companies, I think it's very important that they enter the AI race, and I hope to see more out of them.[00:35:58] Alessio: To me, the, the biggest question with the Google deal is like, who's paying who?[00:36:03] Alessio: Because for the browsers, Google pays Apple like 18, 20 billion every year to be the default browser. Is Google going to pay you to have Gemini or is Apple paying Google to have Gemini? I think that's, that's like what I'm most interested to figure out because with the browsers, it's like, it's the entry point to the thing.[00:36:21] Alessio: So it's really valuable to be the default. That's why Google pays. But I wonder if like the perception in AI is going to be like, Hey. You just have to have a good local model on my phone to be worth me purchasing your device. And that was, that's kind of drive Apple to be the one buying the model. But then, like Shawn said, they're doing the MM1 themselves.[00:36:40] Alessio: So are they saying we do models, but they're not as good as the Google ones? I don't know. The whole thing is, it's really confusing, but. It makes for great meme material on on Twitter.[00:36:51] swyx: Yeah, I mean, I think, like, they are possibly more than OpenAI and Microsoft and Amazon. They are the most full stack company there is in computing, and so, like, they own the chips, man.[00:37:05] swyx: Like, they manufacture everything so if, if, if there was a company that could do that. You know, seriously challenge the other AI players. It would be Apple. And it's, I don't think it's as hard as self driving. So like maybe they've, they've just been investing in the wrong thing this whole time. We'll see.[00:37:21] swyx: Wall Street certainly thinks[00:37:22] NLW: so. Wall Street loved that move, man. There's a big, a big sigh of relief. Well, let's, let's move away from, from sort of the big stuff. I mean, the, I think to both of your points, it's going to.[00:37:33] Meta's $800b AI rebrand[00:37:33] NLW: Can I, can[00:37:34] swyx: I, can I, can I jump on factoid about this, this Wall Street thing? I went and looked at when Meta went from being a VR company to an AI company.[00:37:44] swyx: And I think the stock I'm trying to look up the details now. The stock has gone up 187% since Lamo one. Yeah. Which is $830 billion in market value created in the past year. . Yeah. Yeah.[00:37:57] NLW: It's, it's, it's like, remember if you guys haven't Yeah. If you haven't seen the chart, it's actually like remarkable.[00:38:02] NLW: If you draw a little[00:38:03] swyx: arrow on it, it's like, no, we're an AI company now and forget the VR thing.[00:38:10] NLW: It's it, it is an interesting, no, it's, I, I think, alessio, you called it sort of like Zuck's Disruptor Arc or whatever. He, he really does. He is in the midst of a, of a total, you know, I don't know if it's a redemption arc or it's just, it's something different where, you know, he, he's sort of the spoiler.[00:38:25] NLW: Like people loved him just freestyle talking about why he thought they had a better headset than Apple. But even if they didn't agree, they just loved it. He was going direct to camera and talking about it for, you know, five minutes or whatever. So that, that's a fascinating shift that I don't think anyone had on their bingo card, you know, whatever, two years ago.[00:38:41] NLW: Yeah. Yeah,[00:38:42] swyx: we still[00:38:43] Alessio: didn't see and fight Elon though, so[00:38:45] swyx: that's what I'm really looking forward to. I mean, hey, don't, don't, don't write it off, you know, maybe just these things take a while to happen. But we need to see and fight in the Coliseum. No, I think you know, in terms of like self management, life leadership, I think he has, there's a lot of lessons to learn from him.[00:38:59] swyx: You know he might, you know, you might kind of quibble with, like, the social impact of Facebook, but just himself as a in terms of personal growth and, and, you know, Per perseverance through like a lot of change and you know, everyone throwing stuff his way. I think there's a lot to say about like, to learn from, from Zuck, which is crazy 'cause he's my age.[00:39:18] swyx: Yeah. Right.[00:39:20] AI Engineer landscape - from baby AGIs to vertical Agents[00:39:20] NLW: Awesome. Well, so, so one of the big things that I think you guys have, you know, distinct and, and unique insight into being where you are and what you work on is. You know, what developers are getting really excited about right now. And by that, I mean, on the one hand, certainly, you know, like startups who are actually kind of formalized and formed to startups, but also, you know, just in terms of like what people are spending their nights and weekends on what they're, you know, coming to hackathons to do.[00:39:45] NLW: And, you know, I think it's a, it's a, it's, it's such a fascinating indicator for, for where things are headed. Like if you zoom back a year, right now was right when everyone was getting so, so excited about. AI agent stuff, right? Auto, GPT and baby a GI. And these things were like, if you dropped anything on YouTube about those, like instantly tens of thousands of views.[00:40:07] NLW: I know because I had like a 50,000 view video, like the second day that I was doing the show on YouTube, you know, because I was talking about auto GPT. And so anyways, you know, obviously that's sort of not totally come to fruition yet, but what are some of the trends in what you guys are seeing in terms of people's, people's interest and, and, and what people are building?[00:40:24] Alessio: I can start maybe with the agents part and then I know Shawn is doing a diffusion meetup tonight. There's a lot of, a lot of different things. The, the agent wave has been the most interesting kind of like dream to reality arc. So out of GPT, I think they went, From zero to like 125, 000 GitHub stars in six weeks, and then one year later, they have 150, 000 stars.[00:40:49] Alessio: So there's kind of been a big plateau. I mean, you might say there are just not that many people that can start it. You know, everybody already started it. But the promise of, hey, I'll just give you a goal, and you do it. I think it's like, amazing to get people's imagination going. You know, they're like, oh, wow, this This is awesome.[00:41:08] Alessio: Everybody, everybody can try this to do anything. But then as technologists, you're like, well, that's, that's just like not possible, you know, we would have like solved everything. And I think it takes a little bit to go from the promise and the hope that people show you to then try it yourself and going back to say, okay, this is not really working for me.[00:41:28] Alessio: And David Wong from Adept, you know, they in our episode, he specifically said. We don't want to do a bottom up product. You know, we don't want something that everybody can just use and try because it's really hard to get it to be reliable. So we're seeing a lot of companies doing vertical agents that are narrow for a specific domain, and they're very good at something.[00:41:49] Alessio: Mike Conover, who was at Databricks before, is also a friend of Latentspace. He's doing this new company called BrightWave doing AI agents for financial research, and that's it, you know, and they're doing very well. There are other companies doing it in security, doing it in compliance, doing it in legal.[00:42:08] Alessio: All of these things that like, people, nobody just wakes up and say, Oh, I cannot wait to go on AutoGPD and ask it to do a compliance review of my thing. You know, just not what inspires people. So I think the gap on the developer side has been the more bottom sub hacker mentality is trying to build this like very Generic agents that can do a lot of open ended tasks.[00:42:30] Alessio: And then the more business side of things is like, Hey, If I want to raise my next round, I can not just like sit around the mess, mess around with like super generic stuff. I need to find a use case that really works. And I think that that is worth for, for a lot of folks in parallel, you have a lot of companies doing evals.[00:42:47] Alessio: There are dozens of them that just want to help you measure how good your models are doing. Again, if you build evals, you need to also have a restrained surface area to actually figure out whether or not it's good, right? Because you cannot eval anything on everything under the sun. So that's another category where I've seen from the startup pitches that I've seen, there's a lot of interest in, in the enterprise.[00:43:11] Alessio: It's just like really. Fragmented because the production use cases are just coming like now, you know, there are not a lot of long established ones to, to test against. And so does it, that's kind of on the virtual agents and then the robotic side it's probably been the thing that surprised me the most at NVIDIA GTC, the amount of robots that were there that were just like robots everywhere.[00:43:33] Alessio: Like, both in the keynote and then on the show floor, you would have Boston Dynamics dogs running around. There was, like, this, like fox robot that had, like, a virtual face that, like, talked to you and, like, moved in real time. There were industrial robots. NVIDIA did a big push on their own Omniverse thing, which is, like, this Digital twin of whatever environments you're in that you can use to train the robots agents.[00:43:57] Alessio: So that kind of takes people back to the reinforcement learning days, but yeah, agents, people want them, you know, people want them. I give a talk about the, the rise of the full stack employees and kind of this future, the same way full stack engineers kind of work across the stack. In the future, every employee is going to interact with every part of the organization through agents and AI enabled tooling.[00:44:17] Alessio: This is happening. It just needs to be a lot more narrow than maybe the first approach that we took, which is just put a string in AutoGPT and pray. But yeah, there's a lot of super interesting stuff going on.[00:44:27] swyx: Yeah. Well, he Let's recover a lot of stuff there. I'll separate the robotics piece because I feel like that's so different from the software world.[00:44:34] swyx: But yeah, we do talk to a lot of engineers and you know, that this is our sort of bread and butter. And I do agree that vertical agents have worked out a lot better than the horizontal ones. I think all You know, the point I'll make here is just the reason AutoGPT and maybe AGI, you know, it's in the name, like they were promising AGI.[00:44:53] swyx: But I think people are discovering that you cannot engineer your way to AGI. It has to be done at the model level and all these engineering, prompt engineering hacks on top of it weren't really going to get us there in a meaningful way without much further, you know, improvements in the models. I would say, I'll go so far as to say, even Devin, which is, I would, I think the most advanced agent that we've ever seen, still requires a lot of engineering and still probably falls apart a lot in terms of, like, practical usage.[00:45:22] swyx: Or it's just, Way too slow and expensive for, you know, what it's, what it's promised compared to the video. So yeah, that's, that's what, that's what happened with agents from, from last year. But I, I do, I do see, like, vertical agents being very popular and, and sometimes you, like, I think the word agent might even be overused sometimes.[00:45:38] swyx: Like, people don't really care whether or not you call it an AI agent, right? Like, does it replace boring menial tasks that I do That I might hire a human to do, or that the human who is hired to do it, like, actually doesn't really want to do. And I think there's absolutely ways in sort of a vertical context that you can actually go after very routine tasks that can be scaled out to a lot of, you know, AI assistants.[00:46:01] swyx: So, so yeah, I mean, and I would, I would sort of basically plus one what let's just sit there. I think it's, it's very, very promising and I think more people should work on it, not less. Like there's not enough people. Like, we, like, this should be the, the, the main thrust of the AI engineer is to look out, look for use cases and, and go to a production with them instead of just always working on some AGI promising thing that never arrives.[00:46:21] swyx: I,[00:46:22] NLW: I, I can only add that so I've been fiercely making tutorials behind the scenes around basically everything you can imagine with AI. We've probably done, we've done about 300 tutorials over the last couple of months. And the verticalized anything, right, like this is a solution for your particular job or role, even if it's way less interesting or kind of sexy, it's like so radically more useful to people in terms of intersecting with how, like those are the ways that people are actually.[00:46:50] NLW: Adopting AI in a lot of cases is just a, a, a thing that I do over and over again. By the way, I think that's the same way that even the generalized models are getting adopted. You know, it's like, I use midjourney for lots of stuff, but the main thing I use it for is YouTube thumbnails every day. Like day in, day out, I will always do a YouTube thumbnail, you know, or two with, with Midjourney, right?[00:47:09] NLW: And it's like you can, you can start to extrapolate that across a lot of things and all of a sudden, you know, a AI doesn't. It looks revolutionary because of a million small changes rather than one sort of big dramatic change. And I think that the verticalization of agents is sort of a great example of how that's[00:47:26] swyx: going to play out too.[00:47:28] Adept episode - Screen Multimodality[00:47:28] swyx: So I'll have one caveat here, which is I think that Because multi modal models are now commonplace, like Cloud, Gemini, OpenAI, all very very easily multi modal, Apple's easily multi modal, all this stuff. There is a switch for agents for sort of general desktop browsing that I think people so much for joining us today, and we'll see you in the next video.[00:48:04] swyx: Version of the the agent where they're not specifically taking in text or anything They're just watching your screen just like someone else would and and I'm piloting it by vision And you know in the the episode with David that we'll have dropped by the time that this this airs I think I think that is the promise of adept and that is a promise of what a lot of these sort of desktop agents Are and that is the more general purpose system That could be as big as the browser, the operating system, like, people really want to build that foundational piece of software in AI.[00:48:38] swyx: And I would see, like, the potential there for desktop agents being that, that you can have sort of self driving computers. You know, don't write the horizontal piece out. I just think we took a while to get there.[00:48:48] NLW: What else are you guys seeing that's interesting to you? I'm looking at your notes and I see a ton of categories.[00:48:54] Top Model Research from January Recap[00:48:54] swyx: Yeah so I'll take the next two as like as one category, which is basically alternative architectures, right? The two main things that everyone following AI kind of knows now is, one, the diffusion architecture, and two, the let's just say the, Decoder only transformer architecture that is popularized by GPT.[00:49:12] swyx: You can read, you can look on YouTube for thousands and thousands of tutorials on each of those things. What we are talking about here is what's next, what people are researching, and what could be on the horizon that takes the place of those other two things. So first of all, we'll talk about transformer architectures and then diffusion.[00:49:25] swyx: So transformers the, the two leading candidates are effectively RWKV and the state space models the most recent one of which is Mamba, but there's others like the Stripe, ENA, and the S four H three stuff coming out of hazy research at Stanford. And all of those are non quadratic language models that scale the promise to scale a lot better than the, the traditional transformer.[00:49:47] swyx: That this might be too theoretical for most people right now, but it's, it's gonna be. It's gonna come out in weird ways, where, imagine if like, Right now the talk of the town is that Claude and Gemini have a million tokens of context and like whoa You can put in like, you know, two hours of video now, okay But like what if you put what if we could like throw in, you know, two hundred thousand hours of video?[00:50:09] swyx: Like how does that change your usage of AI? What if you could throw in the entire genetic sequence of a human and like synthesize new drugs. Like, well, how does that change things? Like, we don't know because we haven't had access to this capability being so cheap before. And that's the ultimate promise of these two models.[00:50:28] swyx: They're not there yet but we're seeing very, very good progress. RWKV and Mamba are probably the, like, the two leading examples, both of which are open source that you can try them today and and have a lot of progress there. And the, the, the main thing I'll highlight for audio e KV is that at, at the seven B level, they seem to have beat LAMA two in all benchmarks that matter at the same size for the same amount of training as an open source model.[00:50:51] swyx: So that's exciting. You know, they're there, they're seven B now. They're not at seven tb. We don't know if it'll. And then the other thing is diffusion. Diffusions and transformers are are kind of on the collision course. The original stable diffusion already used transformers in in parts of its architecture.[00:51:06] swyx: It seems that transformers are eating more and more of those layers particularly the sort of VAE layer. So that's, the Diffusion Transformer is what Sora is built on. The guy who wrote the Diffusion Transformer paper, Bill Pebbles, is, Bill Pebbles is the lead tech guy on Sora. So you'll just see a lot more Diffusion Transformer stuff going on.[00:51:25] swyx: But there's, there's more sort of experimentation with diffusion. I'm holding a meetup actually here in San Francisco that's gonna be like the state of diffusion, which I'm pretty excited about. Stability's doing a lot of good work. And if you look at the, the architecture of how they're creating Stable Diffusion 3, Hourglass Diffusion, and the inconsistency models, or SDXL Turbo.[00:51:45] swyx: All of these are, like, very, very interesting innovations on, like, the original idea of what Stable Diffusion was. So if you think that it is expensive to create or slow to create Stable Diffusion or an AI generated art, you are not up to date with the latest models. If you think it is hard to create text and images, you are not up to date with the latest models.[00:52:02] swyx: And people still are kind of far behind. The last piece of which is the wildcard I always kind of hold out, which is text diffusion. So Instead of using autogenerative or autoregressive transformers, can you use text to diffuse? So you can use diffusion models to diffuse and create entire chunks of text all at once instead of token by token.[00:52:22] swyx: And that is something that Midjourney confirmed today, because it was only rumored the past few months. But they confirmed today that they were looking into. So all those things are like very exciting new model architectures that are, Maybe something that we'll, you'll see in production two to three years from now.[00:52:37] swyx: So the couple of the trends[00:52:38] NLW: that I want to just get your takes on, because they're sort of something that, that seems like they're coming up are one sort of these, these wearable, you know, kind of passive AI experiences where they're absorbing a lot of what's going on around you and then, and then kind of bringing things back.[00:52:53] NLW: And then the, the other one that I, that I wanted to see if you guys had thoughts on were sort of this next generation of chip companies. Obviously there's a huge amount of emphasis. On on hardware and silicon and, and, and different ways of doing things, but, y
I spent some time with my friend Milind Shah, who leads Strategy and Digital Solutions at Elevance Health, and he drops wisdom and insights on the state of transformation in healthcare and the role of digital and AI. Take a listen, Milind blends business insights with technology applications and goes really deep in some areas! About Milind: Milind has been in the healthcare industry for over 15 years now and truly enjoys having the opportunity to be a part of having an impact on the industry and truly leaving a legacy. He currently leading up Strategy & Solutions for Carelon Digital Platforms, supporting the overall vision of transforming the company, with a focus on Digital products & solutions focusing on both the Member and Provider. He is responsible for partnering across the enterprise to define the overall Digital focus aligned to the Enterprise strategic priorities, driving Carelon growth/commercialization, and identifying acceleration opportunities through strategic partnerships, while also partnering with Corp Dev on M&A opportunities. A lot of his focus currently is partnering across the Enterprise on areas like transformation through AI and looking at opportunities to leverage the robust “ecosystem” that is being invested in to help accelerate impact at scale for Elevance Health. Throughout his career, Milind has built and led teams that focus on Transformation, Innovation, and Strategy with an emphasis on Growth Strategy, M&A, Post Merger Integration, and Disruptive/Exponential Product and he's had some great opportunities to do things like running Innovation Studios at Salesforce to being a part of the Senior Leadership team at Humana to help with several of their transformation initiatives as the company moved to focusing on their Growth Strategy. Find him at: LinkedIn: https://www.linkedin.com/in/milinds/
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
First, we talk about the Bengaluru-based start-up CEO, Suchana Seth, who has been taken into custody for allegedly murdering her four-year-old son at a hotel in Goa. In this segment, we are joined by The Indian Express' Pavneet Singh Chadha, who tells us how this crime unfolded.Second, we talk about Milind Deora's resignation from the Congress to join the Shinde Sena in Mumbai. To understand the reasons behind this, Indian Express' Alok Deshpande joins us in this segment. 12:55Lastly, we discuss Maldivian President Mohamed Muizzu's deadline for India to withdraw its military personnel from the country, amid the ongoing diplomatic row between Maldives and India. 22:07Hosted by Rahel PhiliposeWritten and Produced by Rahel Philipose, Shashank Bhargava and Niharika NandaEdited and Mixed by Suresh Pawar
Listen to the SBS Hindi news from India. 15/01/2024
Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers | Faculty Presentation 2: Emerging Management Approaches for Patients with Advanced BTCs — Milind Javle, MD CME information and select publications
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerMilind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.Co-Chair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
In this episode of Procurement Reimagined, brought to you by Gatekeeper, your host, Daniel Barnes, is joined by Milind Deepak Tailor, Global Head, Services Procurement & Vendor Management at Diebold Nixdorf. Join Daniel and Milind as they discuss what it means to be a trusted partner and value creator, the key characteristics of a trusted partner, as well as why value cannot be considered in isolation. Milind Deepak Tailor is a Global Supply Chain, Procurement, and Operations Leader with a proven track record in program management, optimising supply chains, and delivering significant cost savings. He is the current Global Head of Services Procurement and Vendor Management at Diebold Nixdorf, a world leader in connected commerce producers of cutting-edge product technology, multi-vendor software, and service for financial and retail customers. There, he is responsible for providing influence and guidance to ensure best-in-class procurement across the global organisation. Episode Resources: Milind Deepak Tailor on LinkedIn Diebold Nixdorf Website Procurement Reimagined Podcast Daniel Barnes LinkedIn If you enjoyed this episode, then please either:Subscribe, rate, and review on Apple Podcasts Follow on Spotify Check out Procurement Reimagined Podcast Book a call with a Vendor and Contract Management Expert - https://www.gatekeeperhq.com/book-gk-demo-step-1 GATEKEEPER'S GUIDE TO VENDOR LIFECYCLE MANAGEMENT Actionable checklists, tips, and best practices. Download the ebook now for FREE: https://www.gatekeeperhq.com/free-vendor-management-ebook Would you or someone you know be a great fit for the podcast? Please fill out the Procurement Reimagined Guest Questionnaire Procurement Reimagined Podcast is handcrafted by our friends over at fame.so Previous guests include Sarah Kaye of Spin, Hannah MacDonald of Monzo Bank, Dave Jones MCIPS of Procmentum Limited, Andra Fola of Solutionary Minds, Natalia Pilipchak of Mobile Tele Systems, Rees Thomas of Graze, Nadia Stoykov of Tesca Group, Canda Rozier of Collabra Consulting, Elouise Epstein of Kearney, and Matthew Booth of PM Group. Check out our five most downloaded episodes: Reimagining Procurement by Filling Implementation Gaps with Nadia Stoykov, Chief Procurement and Supply Chain Officer at Tesca Group Reimagining Procurement in an Economic Downturn with Andra Fola, Co-Founder of Solutionary Minds Aligning Cost Control and Cost Cutting to Drive Value with Sarah Kaye, Vice President of Procurement at Spin Reimagining Procurement as the Hidden Treasure for Business Growth with Natalia Pilipchak, Transformation and Excellence Director at Mobile Tele Systems A Playbook for Digitalising Procurement with Rees Thomas, Head of Procurement at Graze
In this episode, we discuss the career of Dr. Milind Dawande. Dr. Dhawande was elected as a Production and Operations Management Society Fellow in 2022. Designation as a POMS Fellow is the most prestigious honor awarded by the Production and Operations Management Society, and is given for life. It is intended to recognize POMS members who have made exceptional intellectual contributions to our profession and Society through their research and teaching. Although loyal service to the Society, in administrative, elected, or editorial assignments, is not by itself a sufficient qualification for this award, it can strengthen the case of a member who has also become a thought-leader in our field. To be eligible a candidate must have demonstrated commitment to furthering the objectives of POMS (as evidenced by such indicators as membership in the Society, and active participation in POMS Colleges and meetings).
जागतिक क्रिकेटचा चेहरामोहरा बदलण्यास कारणीभूत ठरलेल्या 'त्या' सामन्याला २५ जून, २०२३ ला तब्बल ४० वर्षं पूर्ण होत आहेत. १९८३ वर्ल्ड कपचा भारत आणि वेस्ट इंडिजमधील खेळला गेलेला अंतिम सामना लॉर्ड्स मैदानावरून 'याचि देही, याचि डोळा' पाहिलेले मिलिंद कनमाडीकर - ज्यांचे वडिल अनंत कनमाडीकर हे तेव्हा BCCI चे सचिव होते - सांगत आहेत अंतिम सामन्याच्या त्यांच्या आठवणी.It's the 40th anniversary of the match that changed the game of cricket forever. Exactly four decades since Kapil's Devils defeated the mighty West Indies in the 1983 World Cup final at Lord's on June 25, 1983, Milind Kanmbadikar - son of then BCCI secretary Anant Kanmadikar - recalls watching the game from the Members' stand at the iconic stadium.
I'm delighted to feature the master bansuri player Milind Date, who joined me from his home in Pune, India, and played his flutes as well as shared his perspectives from his life in music. As always, check the timestamps below for both the music and the many topics we covered. Milind spoke to me about his studies with the legendary Pandit Hariprasad Chaurasia, of his fusion projects especially in South Korea, he had a great story about a memorable concert he played in Toronto, he talked about his extensive travels in India and internationally. He has a large and varied discography, and has composed music for many films: https://www.milind.date/ Like all my episodes, this is available both as a podcast and video, with a transcript all linked to my website: https://www.leahroseman.com/episodes/milind-date-bansuri-player Please help me continue this series! https://ko-fi.com/leahroseman Timestamps: (00:00) Intro (01:46) bansuri flute (03:28) Sunand Bhairav (04:50) early rock music influences, fusion music Hariprasad Chaurasia (11:01) Korean tours and collaborations (17:59) solo 6 month trip in India 2021 (26:11) folk tune from Uttarakhand region (30:01) different folk traditions in India (32:18) Milind's collection of flutes in different keys (35:01) differences between Hindustani and Carnatic music (38:09) system of gharanas, studies with Hariprasad Chaurasia (55:49) Zakir Hussain (01:05:31) writing film music, notation, Western classical musicians (01:11:31) around the world tour 2013 (01:12:58) performances in Canada (01:20:00) music as meditation (01:23:14) teaching and learning (01:29:56) flute performance --- Send in a voice message: https://podcasters.spotify.com/pod/show/leah-roseman/message
This week, please join author Milind Desai and Associate Editor Mark Link as they discuss the article "Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr Greg Hundley, Associate Editor, Director of the Poly Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Oh, Greg. Today's feature paper is just so, so important. It's the long-term follow up or the longer term follow up of the VALOR-HCM trial. And this, if I can remind you, examined the effect of mavacampten on the need for septal reduction therapy in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy. So we're going to hear the results through 32 weeks, but not until we discuss the other papers in today's issue. And I'd like to go first. I'd like to tell you about a paper that really provides the foundation for deciphering chamber selective gene transcription. So in this study from Dr. William Pu of Boston Children's Hospital and colleagues, authors mapped the chromatin features of atrial and ventricular cardiomyocytes and nominated candidate chamber selective enhancers based on differential features. The candidate enhancers were tested in vivo using adeno associated virus delivered massively parallel reporter assay leading to identification of 229 chamber selective enhancers. They then characterized chromatin features of these chamber selective enhancers and used dense mutagenesis to identify their essential features. Altogether the study suggested that estrogen-related receptor promoted ventricular chamber selective enhancer activity. They validated this prediction by showing that estrogen-related receptor inactivation led to loss of ventricular cardiomyocyte identity. So in aggregate, the studies yielded a rich resource of chamber selective chromatin features and chamber selective enhancers, and began to unravel the molecular basis for chamber selective transcriptional programs. Dr. Greg Hundley: Wow. So Carolyn, estrogen-related receptor promotion and then inactivation and finding really very interested preclinical results. So tell us now what are the clinical implications of this very nice study. Dr. Carolyn Lam: Wow. I mean, there are just so many implications. It can facilitate functional interpretation of genetic associations between variants and cardiac disease. Of course, it opens the doors to potential gene therapies and regenerative medicine and finally, identification of transcription regulators of the chamber identity really yield important mechanistic insights into the pathogenesis of important diseases like atrial fibrillation and cardiomyopathy. Dr. Greg Hundley: Wow, Carolyn, beautifully summarized. Well, my next paper pertains to COVID vaccines. So Carolyn, as we have seen SARS-CoV-2 targeted mRNA vaccines are a life-saving medical advancement developed to combat, of course, the COVID-19 pandemic. But in rare cases, some individuals can develop myocarditis following these mRNA vaccinations. Cases of adolescents and young adults developing post vaccine myocarditis have been reported globally, although the underlying immuno profiles of these individuals, they really haven't been described in detail. So these authors led by Dr. Lael Yonker from Massachusetts General Hospital, performed extensive system serology SARS-CoV-2 specific T-cell analysis and cytokine and SARS-CoV-2 antigen profiling on blood samples collected from adolescents and young adults either developed myocarditis or were asymptomatic following SARS-CoV-2 targeted mRNA vaccination. Dr. Carolyn Lam: Wow. Wow. Important question. Everyone's interested in the results. So what did they find? Dr. Greg Hundley: Right, Carolyn. So 16 cases with post vaccine myocarditis and 45 asymptomatic vaccinated controls were enrolled with extensive antibodies profiling, including assessment for autoantibodies or antibodies against the human relevant virome. And Carolyn, they found that T-cell responses were essentially indistinguishable from controls despite a modest increase in cytokine production. Notably, markedly elevated levels of full length spike protein unbound by antibodies were detected in the plasma of individuals with post vaccine myocarditis, a finding that was absent. It was absent in the asymptomatic vaccinated controls. So Carolyn, in conclusion, immunoprofiling of vaccinated adolescents and young adults revealed that the mRNA vaccine-induced immune responses did not differ between individuals that developed myocarditis versus individuals that did not. However, free spike antigen was detected in the blood of adolescents and young adults who developed post mRNA vaccine myocarditis. Now while this finding does not alter the risk benefit ratio favoring vaccination against COVID-19 to prevent severe clinical outcomes, it may provide some insight into the potential underlying etiology associated with post mRNA vaccine-induced myocarditis. Carolyn, this is accompanied by a wonderful editorial by Dr. Biykem Bozkurt indicating that these results raise a question as to why the circulating spike protein levels remain elevated despite adequate levels and functionality of the anti-spike antibodies. Well, Carolyn, we do have some other articles in the issue and from the mailbag we have a research letter from Professor Cho entitled PERM1 Protects the Heart From Pressure Overload Induced Dysfunction by Promoting Oxidative Metabolism. Also, there's a new drugs and devices piece from Professor Kabatano entitled Pharmacology and Clinical Development of Factor XI inhibitors. And then Tracy Hansen has a wonderful cardiology news summary regarding articles entitled The Study Reveals Rapid Intestinal Adaptations after Switching to High Fat Diet From Cell Research. Another article entitled New Insights into Immunotherapy Related Myocarditis from Nature. And finally, an article entitled Scientist Identified Genetic Variants Linked to Longevity published in the Journal of Science. Dr. Carolyn Lam: Wow. Interesting. There's also an exchange of letters between Drs. Monzo and Shah regarding the article, “Metabolomic Profiling of Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction.” That is a Perspective piece by Dr. Davenport on contrast induced acute kidney injury and cardiovascular imaging, danger or distraction? Wow. What a beautiful issue. Thank you so much, Greg. Let's go to our feature discussion, shall we? Dr. Greg Hundley: Absolutely. Welcome, listeners, to this feature discussion on March 14th. And we have with us today Dr. Milind Desai from Cleveland Clinic in Cleveland, Ohio, and our own associate editor, Dr. Mark Link from University of Texas Southwestern Medical Center in Dallas, Texas. Welcome, gentlemen, Milind, we'll begin with you and bringing to us this study of mavacampten. Can you describe for us some of the background information that went into the preparation of this study, and what was the hypothesis that you wanted to address? Dr. Milind Desai: Thank you to the editorial staff, Dr. Hundley and the editorial staff at Circulation. So yes, mavacampten, as we know, is a novel first in class cardiac myocin inhibitor that was developed in the context of managing patients with hypertrophic obstructive cardiomyopathy. So the preliminary early stage studies have shown that it helped significantly in reducing outflow tract gradients as well as improved symptoms. But we wanted to take the conversation a bit further. In highly symptomatic patients, the current standard of care treatment is septal reduction therapy, which requires an experienced center and an experienced set of providers. So what we wanted to see was in such patients that are referred for septal reduction therapy, what does mavacampten do versus placebo? So does it reduce the need for septal reduction therapy? We divided the study into three parts. The first part was the placebo controlled 16 week study. The second part was we wanted to see what happens when the placebo arm crossed over to mavacampten and the mavacampten arm continued long-term. And that was the genesis of the study that we are discussing today. Dr. Greg Hundley: Very nice. So we've got a planned study, patients with hypertrophic cardiomyopathy, they ordinarily, because of guideline related therapeutic recommendations would undergo septal reduction therapy, but before that you're going to randomize patients to mavacampten versus a placebo. So we've sort of described a little bit the study design, and let's clarify specifically perhaps the study population and how many patients did you enroll? Dr. Milind Desai: Yes. In the original study, we enrolled 112 patients, 56 to mavacampten and 56 to placebo. After week 16, four patients, two of which underwent SRT and two withdrew consent. So essentially for the 32 week analysis, we had 108 patients, 56 in the mavacampten group and 52 in the placebo group that crossed over to mavacampten. So 108 patients. Dr. Greg Hundley: Very nice. So Milind, what were your study results? Dr. Milind Desai: Yes. What we found was at week 16, we have previously demonstrated that the group that got randomized mavacampten had a significant reduction in outflow tract radius, both resting and Valsalva, as well as biomarkers. And at week 16, what we found was 82% patients from the original group did not meet criteria for septal reduction therapy. So a hundred percent to begin with, 82%, that was at week 16. What we wanted to see, is the effect continued longer lasting and what happens to the placebo group that crossed over? So essentially what we found was at week 32, 89% of the total population no longer met criteria for septal reduction therapy. In addition to that, the mavacampten group continued to have reduced outflow tract gradients, continued improvement in Kansas City Score as well as biomarkers. But more importantly, the similar findings were demonstrated in the placebo arm that cross over to the mavacampten where, again, a significant proportion continued to show improvement in outflow tract gradient, Kansas City Score, as well as biomarker. The important point here in this study was at week 32, 95% patients chose to remain on medical therapy as opposed to going for SRT. Remember, a hundred percent patients were referred at the outset to undergo SRT. Dr. Greg Hundley: And Milind, did you notice any differences in your study results based on the age of the patients or based on their sex? Dr. Milind Desai: No, actually, we did not. This had a beneficial effect across gender, age, all the other variables. In fact, this is one of the strengths of the study because almost 50% patients that were randomized were women. So this was well represented across different genders. Dr. Greg Hundley: And then you mentioned a marked reduction in the gradient across the left ventricular outflow tract. What about the patient's symptomatology? Did you notice differences there? Dr. Milind Desai: There were significant improvement in patient symptomatology. More than 70% patients had a improvement in one NYHA class, 30% or thereabouts had a significant improvement in two NYHA class compared to placebo. So yes, there was a significant improvement in their functional capacity. Dr. Greg Hundley: And then last question, hypertrophic cardiomyopathy. Were most of these patients, was this concentric? Was this asymmetric septal hypertrophy? What was the breakdown, if you will, of the morphology of the left ventricles? Dr. Milind Desai: The vast majority of the patients had asymmetric septal hypertrophy, the characteristic with dynamic outflow tract gradient. There were some patients, but the vast majority of them were asymmetric septal hypertrophy. Dr. Greg Hundley: Very nice. Well, listeners, we're going to turn to our associate editor, Dr. Mark Link. Mark, this really sounds striking, randomized clinical trial, patients needing septal reduction therapy. They're randomized. The group randomized to mavacampten has marked reductions in left ventricular outflow tract gradient, symptomatology, and so much so that they no longer met the criteria for septal reduction therapy. I know you have a lot of papers come across your desk. Can you help us put what seemingly are exciting results into the context of other studies pertaining to mavacampten as well as treatment for patients with symptomatic hypertrophic cardiomyopathy? Dr. Mark Link: Yeah. There are very few randomized studies in patients with hypertrophic cardiomyopathy, probably only two that I know of. And mavacampten is a very exciting new drug that's a novel drug, a novel mechanism and has the potential to really improve life for our patients with hypertrophic cardiomyopathy. So this is a longer term study of mavacampten that's ever been published. So yeah, it was very exciting for us to look at this data to see how the patients did and we were very, very pleased to publish this paper. Dr. Greg Hundley: Very nice. So maybe, Milind, turn this back to you. What do you think are some of the next studies that'll be performed really in this arena of research? Dr. Milind Desai: Yes. Obviously, as Mark pointed out, this was one of the longest term studies, but we need to do a lot longer. So long term extension studies are ongoing. We should be evaluating one year outcomes in this specific population as well as longer, number one. Number two, I think in the grand scheme of things, this is a brand new class. So overall it is obviously now FDA approved and post-marketing survey and analysis should help us see a signal in terms of outcomes, mortality, et cetera. In your sister journal Circulation Imaging, we have simultaneously also published that mavacampten is causing a significant improvement in the structural changes like diastolic dysfunction, like LV mass, LA volume index. So we need to see how that plays out. Another important piece is about 30% patients have non-obstructive hypertrophic cardiomyopathy and there's no real treatment for this group and there's no outflow tract obstruction to cure in this. So we have just recently launched and started to randomize ODYSSEY HCM trial, which is checking the role of mavacampten versus placebo in non-obstructive HCM group. And I am fortunate. So it's a multi-centered trial that is being led out of Cleveland Clinic. So more data in that exciting field. But overall, this entire field of hypertrophic cardiomyopathies is exploding with multiple randomized controlled trials. There's another drug that is being tested in phase three trials, cardiac myocin inhibition. So that story also remains to see how that plays out. So a lot of stuff that is happening in this space. And then now there's gene therapy emerging. Dr. Greg Hundley: Right. And Milind, since you have quite extensive experience here, for our listeners, what side effect profiles have you observed in some of these patients? And if someone is considering working with placing a patient on this therapy, what are some of the considerations that they should be thinking about? Dr. Milind Desai: So that's a very important question. So the drug, as you are aware, was approved by the FDA under the REMS or Risk Evaluation Mitigation Strategy program. So the fundamental thing is both the patient and the physician have to sign up for the REMS program. The biggest issue that FDA wants us to be careful about is this is a cardiac myosin inhibitor. So it means we have to be very careful about over inhibition of the cardiac myosin and a drop in ejection fraction and its downstream ramifications including heart failure. The other aspect is drug-drug interaction because of its pathway of metabolism. So these are the two key things we have to be on the careful about. Now you asked my clinical experience. So we have been prescribing this for almost six, seven months, and we have dozens of patients on this using the REMS strategy, careful echocardiographic monitoring and clinical decision making. So far, we have been very successfully able to navigate these patients without any major adverse events. And the vast majority of the patients, true to form as we have shown in the clinical trial, are doing very, very well in terms of their symptoms, their need for SRT, as well as their markers, including outflow tract gradient. Dr. Greg Hundley: Very nice. And Mark, turning to you from the perspective of an electrophysiologist, what potential future studies do you see forming in this space? Dr. Mark Link: Yeah, very similar to Milind. And I think the long term efficacy and safety really has to be looked at. There's a signal for potential harm in that the EF can drop, and Milind mentioned that too, that we have to learn how to deal with that. The way to prescribe it now, you have to be in a special program. You have to be trained, you have to agree to get echoes every three months, I believe it is, essentially for the rest of their life. So we need to see what happens long term with these drugs and we need to know how to dose them and how to do it safely. Dr. Greg Hundley: Very nice. So for our listeners, really a class of drugs that is emerging and at this time only under really strictly supervise protocols. Well, from the perspective of our listeners, we want to thank Dr. Milind Desai and our own associate editor, Dr. Mark Link, for bringing us this informative new early randomized trial study results indicating that in severely symptomatic patients with obstructive hypertrophic cardiomyopathy, 32 weeks of mavacampten treatment showed sustained reduction in the proportion proceeding to septal reduction therapy. Well, on behalf of Petter, Carolyn and myself, we want to wish you a great week and we will catch you next week on The Run. This program is copyright of the American Heart Association, 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.
Season 13, Ep 23: Coming to you at sunset from the old VCA ground in Nagpur, where Damien Martyn hit that six onto the press box roof in 2004, this is at last our first weekly show from India. The old stadium a different place now, much more low key than when it hosted Tests, but our friend Milind bhai from the security detail showed us around. This week on the show, the fallout from Australia's Test loss at the other VCA ground, the women's T20 World Cup gets underway with some serious upsets, Jofra Archer bursts back into the England one-day team while their Test side prepares in New Zealand without Trent Boult, Aaron Finch retires, the Big Bash finishes up, and West Indies play out a fun Test match against Zimbabwe. Join us on the roof Your Nerd Pledge number for this week: 1.80 - Bernhard Sayer Join us doing the Edinburgh half-marathon on 28 May: Register here or email finalwordcricket@gmail.com. To donate to Lord's Taverners for that run, link here. To learn about their other projects, join their mailing list at bit.ly/tavssignup. Send us a Nerd Pledge at patreon.com/thefinalword Find previous episodes at finalwordcricket.com 20% off primo WoodstockCricket.co.uk bats with the code TFW20 Title track by Urthboy Learn more about your ad choices. Visit megaphone.fm/adchoices
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/KST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How are you pushing back against HCM in your practice? In PeerView's latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM; Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner; Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM; and Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management.
In Episode #115, we deconstruct Milind Mehere's peak performance playbook—from their favorite book to the tiny habit that's had the biggest impact on their life. Milind Mehere is the Founder and CEO of Yieldstreet. We cover the ABCDE of building a company, the importance of gratitude, and the impact of blockchain on private markets. “Be bright, be brief, be gone.” – Milind Mehere EPISODE GUIDE (LINKS, QUOTES, NOTES, AND BOOKS MENTIONED) https://www.danielscrivner.com/notes/milind-mehere-playbook FULL TEXT TRANSCRIPT https://www.danielscrivner.com/notes/milind-mehere-playbook-transcript/ CHAPTERS In this episode, we deconstruct Milind Mehere's peak performance playbook—from their favorite book to the tiny habit that's had the biggest impact on their life. In it we cover: 00:00:00 – Introduction 00:02:09 – The impact of blockchain on private markets 00:03:16 – Adaptability as a superpower 00:04:59 – Learning from mentors, both personal and public 00:07:09 – Be bright, be brief, be gone. 00:09:14 – The ABCDE of building a company 00:12:19 – Leadership and Self-Deception, plus American Aristocracy 00:13:49 – The importance of gratitude ABOUT MILIND MEHERE Milind Mehere is co-founder and CEO of Yieldstreet. Milind's background is fascinating. Before founding Yieldstreet in 2014, Milind founded and scaled several other companies, including Yodle, which he scaled to $220 million in annual revenue before being acquired by web.com. Over the last eight years, Yieldstreet has built one of the largest private investment platforms in the world. To date, they brought on over 377,000 members that have invested more than $1.5 billion, and Yieldstreet has paid out over $196 million in interest alone. In this episode, Milind shares why he's been fascinated with blockchain and the problems it can solve, including KYC for platforms like Yieldstreet as well as why his superpower is adaptability, and how that's helped him as a serial entrepreneur. He shares some of his favorite books, including, Leadership and Self Deception and The Richest Man in Babylon, as well as why he loves the phrase, "Be bright, be brief, be gone," and why, if he could go back in time, he'd tell his younger self to take even more risks.
Listen to one of our favorite moments from tomorrow's 20 Minute Playbook episode featuring Milind Mehere of Yieldstreet. In it, Milind shares his favorite books, tools, habits, and more. Learn more about your ad choices. Visit megaphone.fm/adchoices
Milind Mehere is an award-winning entrepreneur with a track record of building large scalable businesses and creating new product categories. Milind is the Founder and CEO of Yieldstreet, a next-generation digital investment platform reimagining the way wealth is created by providing access to private markets previously reserved only for institutions and the ultra-wealthy. Yieldstreet was named Financial Times's 12th Fastest Growing Company in the US, and for two consecutive years, Yieldstreet was named one of the top 50 Fastest-Growing Companies by Inc. Previously, Milind Co-founded and scaled Yodle (an ad-tech platform for SMBs) to $200M+ in revenue and 1,400 employees. Yodle was ranked four times in the Inc. 500 list and was acquired by Web.com for $342M in 2016. Milind was named an Innovation Fellow at Columbia University's Lang Center, and is an international keynote speaker, having spoken at Forbes, Bloomberg, Cheddar, LendIt, Citi Bank, Goldman, Columbia, and Harvard among others.
© 2020-2025 Ivy Podcast Discovery LLC
